Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy A STROBE-compliant observational study

Esatoglu S. N., Hatemi G., Ugurlu S., Gokturk A., Tascilar K., Ozdogan H.

MEDICINE, cilt.96, sa.34, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 96 Sayı: 34
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1097/md.0000000000007859
  • Dergi Adı: MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • İstanbul Üniversitesi Adresli: Evet

Özet

There are no treatment modalities, which were proven to prevent the deposition of amyloid, proteinuria, and loss of renal function due to amyloidosis. Anti-tumor necrosis factor agents (anti-TNFs) were shown to decrease the production of serum amyloid A protein. We aimed to evaluate the long-term efficacy and safety of anti-TNFs in secondary (AA) amyloidosis patients treated in a single center.